| 133 | 2 | 89 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨Xa因子抑制剂治疗外周静脉置入中心静脉(PICC)导管相关血栓的疗效及安全性。方法:1例晚期乳腺癌患者PICC置管后4 d,静脉彩超检查显示PICC管周血栓形成,予利伐沙班20mg/d,口服48 d。结果:静脉彩超检查复查示PICC管周血流通畅,治疗过程无出血事件发生。结论:Xa因子抑制剂可作为中心静脉导管相关血栓有效、安全的药物。
Abstract：Objective: To investigate the treatment efficacy and safety of direct factor Xa inhibitor in thrombus related to peripherally inserted central catheter( PICC). Methods: In one patient with advanced breast cancer patients,venous color Doppler identified peri-catheter thrombosis at 4 d after placement of PICC. Oral rivaroxaban 20 mg/d was administered for 48 d. Results: Follow-up with venous color Doppler showed patency of blood flow around PICC. No hemorrhagic event occurred during the course of treatment. Conclusion: Factor Xa inhibitor can be used as an effective and safe agent for treatment of PICC-related thrombosis.
[1]Cronin-Fenton DP,Sndergaard F,Pedersen LA,et al.Hospitalisation for venous thromboembolism in cancer patients and the general population:a population-based cohort study in Denmark,1997-2006[J].Br J Cancer,2010,103(7):947-953.
[2]Khorana AA.Venous Thromboembolism and Prognosis in Cancer[J].Thromb Res,2010,125(6):490-493.
[3]杨春明.外科学原理与实践[M].2版.北京:人民卫生出版社,2003.
[4]Folsom AR,Delaney JA,Lutsey PL,et al.Associations of factor VIIIc,D-dimer,and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality[J].Am J Hematol,2009,84(6):349-353.
[5]Johnson MJ,Shyar DL,Maraveya SA,et al.Diagnosis and management of people with venous thromboembolism and advanced cancer:how do doctors decide?A qualitative study[J].BMC Med Inform Decis Mak,2012,12(1):75-88.
[6]Ben DB,Derbali F,Boussama F,et al.[Thrombosis and cancer:retrospective study of 17 cases].[J].Tunis Med,2012,90(7):548-551.
[7]Abu SF,Norris L,O'Toole S,et al.Venous thromboembolism in ovarian cancer:incidence,risk factors and impact on survival.[J].Eur J Obstet Gynecol Reprod Biol,2013,170(1):214-218.
[8]Mokri B,Mariani A,Heit JA,et al.Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer[J].Int J Gynecol Cancer,2013,23(9):1684-1691.
[9]李琦.肿瘤患者PICC相关上肢静脉血栓形成的临床分析[D].浙江大学,2015.
[10]吴红娟,陈雪峰,张美英,等.肿瘤患者PICC置管主要并发症及其相关因素分析[J].中华护理杂志,2008,43(2):134-135.
[11]Khorana AA,Kuderer NM,Culakova E,et al.Development and validation of a predictive model for chemotherapyassociated thrombosis[J].Blood,2008,111(10):4902-4907.
[12]Cabral KP,Ansell JE.The role of factor Xa inhibitors in venous thromboembolism treatment[J].Vasc Health Risk Manag,2015,11:117-123.
[13]Quinlan DJ,Eikelboom JW,Dahl OE,et al.Association between as ymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery[J].J Thromb Haemost,2007,5(7):1438-1443.
[14]Levitan B,Yuan Z,Turpie AG,et al.Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty[J].Vasc Health Risk Manag,2014,10:157-167.
[15]Trujillo T,Dobesh PP.Clinical Use of Rivaroxaban:Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications[J].Drugs,2014,74(14):1587-1603.
[15]Castellucci LA,Cameron C,Le GG,et al.Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism:systematic review and network metaanalysis[J].Bmj,2013,347(aug301):f5133.
[16]Kearon C,Akl EA,Ornelas J,et al.Antithrombotic Therapy for VTE Disease:CHEST Guideline and Expert Panel Report[J].Chest,2016,149(2):315-352.
基本信息:
中图分类号:R543
引用信息:
[1]刘芯,张还珠.Xa因子直接抑制剂治疗中心静脉导管相关血栓的疗效介绍[J].广州医科大学学报,2017,45(05):31-33.
2017-10-15
2017-10-15